CLL - Chronic lymphoid leukemia

  1. A phase 3 multicenter, randomized, open-label study of standard chemotherapy plus rituximab versus venetoclax plus rituximab versus venetoclax plus obinutuzumab versus venetoclax and ibrutinib plus obinutuzumab in physically fit patients with previously untreated chronic lymphocytic leukemia without TP53 del/mut. CLL13/GAIA
    Primary researcher: Vesa Lindström
 

 Contact information

 
haluantutkimuspotilaaksi@hus.fi
tel. +358 50 427 0680